Company:  ALLERGAN INC (AGN)
Form Type:  10-K
Filing Date:  2/26/2013 
CIK:  0000850693 
Address:  2525 DUPONT DRIVE 
City, State, Zip:  IRVINE, California 92612 
Telephone:  (714) 246-4500 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$166.61  
Change: 
0.96 (0.58%)  
Trade Time: 
Apr 24  
Market Cap: 
$49.83B
Description of Business
We are a multi-specialty health care company focused on developing and commercializing innovative pharmaceuticals, biologics, medical devices and over-the-counter products that enable people to live life to its full potential - to see more clearly, move more freely and express themselves more fully. We discover, develop and commercialize a diverse range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets in more than 100 countries around the world. We are also a pioneer in specialty pharmaceutical, biologic and medical device research and development. Our research and development efforts are focused on products and technologies related to the many specialty areas in which we currently operate as well as new specialty areas where unmet medical needs are significant. In 2013, our research and development expenditures were approximately 16.
Register for EDGAR Pro and access this filing in:     
  FORM 10-K
    PART I
      Item 1. Business
        NAME AND TITLE
      Item 1A. Risk Factors
      Item 1B. Unresolved Staff Comments
      Item 2. Properties
      Item 3. Legal Proceedings
      Item 4. Mine Safety Disclosures
    PART II
      Item 5. Market For Registrant's Common Equity, Related ...
      Item 6. Selected Financial Data
      Item 7. Management's Discussion and Analysis of Financial ...
        Results of Operations
        Liquidity and Capital Resources
      Item 7A. Quantitative and Qualitative Disclosures About ...
      Item 8. Financial Statements and Supplementary Data
      Item 9. Changes in and Disagreements with Accountants on ...
      Item 9A. Controls and Procedures
      Item 9B. Other Information
    PART III
      Item 10. Directors, Executive Officers and Corporate Governance
      Item 11. Executive Compensation
      Item 12. Security Ownership of Certain Beneficial Owners and ...
      Item 13. Certain Relationships and Related Transactions, and ...
      Item 14. Principal Accounting Fees and Services
    PART IV
      Item 15. Exhibits and Financial Statement Schedules
    BALANCE SHEET
    SIGNATURES
    Report of Independent Registered Public Accounting Firm
    Report of Independent Registered Public Accounting Firm
    BALANCE SHEET
    INCOME STATEMENT
    STOCKHOLDERS EQUITY
    CASH FLOW
    NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
      Note 17: Subsequent Events
    VALUATION AND QUALIFYING ACCOUNTS
  EXHIBIT 10.15
  EXHIBIT 10.20
  EXHIBIT 10.21
  EXHIBIT 10.40
  EXHIBIT 10.51
  EXHIBIT 10.53
  EXHIBIT 21
    SUBSIDIARIES
  EXHIBIT 23.1
    CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
  EXHIBIT 31.1
    CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
  EXHIBIT 31.2
    CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
  EXHIBIT 32
    Certification of Principal Executive Officer
BROKERAGE PARTNERS